Business Context and Reporting Period
This Form 8-K was filed by OrthoPediatrics Corp. on December 14, 2018, reporting events occurring on December 13, 2018. The registrant is an emerging growth company incorporated in Delaware, specializing in surgical systems for pediatric orthopedic care.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory disclosure regarding a new product launch rather than financial performance data.
Material Changes
The primary material event is the full-scale U.S. launch of the Company's 26th surgical system, the RESPONSE 4.5/5.0mm System. This launch follows the receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance in October 2018. The new system expands product offerings for treating complex scoliosis in smaller stature patients at a younger age.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the product launch and its clinical application. The filing does not contain specific financial guidance, updated outlooks, or a discussion of risks and contingencies beyond the standard regulatory disclosure language. No unusual items were reported.
Investor Verification Checklist
- Verify the commercial adoption rate and revenue impact of the newly launched RESPONSE 4.5/5.0mm System.
- Confirm the timeline for the FDA 510(k) clearance received in October 2018.
- Review the full text of the press release (Exhibit 99.1) for additional details on market strategy.
- Monitor upcoming quarterly reports for financial results reflecting this product expansion.